Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cafedrine + theodrenaline + urapidil
- Development stage
- Preclinical
- Lead developer
- Ratiopharm
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of cafedrine, theodrenaline, and urapidil that was investigated in clinical trial NCT01311414 for its effects on cerebral oxygenation. Cafedrine is a chemical linkage of norephedrine and theophylline, while theodrenaline is formed from theophylline and noradrenaline. The cafedrine/theodrenaline component (typically in a 20:1 ratio) is known to increase mean arterial pressure by enhancing cardiac preload, stroke volume, and cardiac output.
02
Targets
ADRB1 (β1)PDE (Phosphodiesterase family)ADRA1A (α1A)
Beyond the preview
Go deeper on cafedrine + theodrenaline + urapidil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cafedrine + theodrenaline + urapidil.